Sana Biotechnology, Inc. (SANA): Capital Expenditures
$938.0K
Year ended 2025-12-31
$2.82M
Trailing 12 months to 2026-06-30
-64.4%
3-year compound annual growth
-47.7%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $938.0K | -97.2% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $33.43M | +66.9% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $20.03M | -4.0% | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | $20.88M | -30.1% | 2025-03-17, From 2022-01-01 |
| 2021-12-31 | $29.86M | +25.1% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $23.87M | -8.6% | 2023-03-16, From 2020-01-01 |
| 2019-12-31 | $26.12M | n/a | 2022-03-16, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $938.0K | -97.2% |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $386.0K | -44.4% |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $602.0K | +514.3% |
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | $794.0K | -30.8% |
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $49.0K | n/a |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $4.70M | +17.9% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $2.41M | -0.9% |
| Vor Biopharma Inc. (VOR) | 2025-12-31 | $941.0K | +310.9% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $133.0K | n/a |
Compare SANA, ALLO, SRRK, MAZE side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗